Who are Liposomal Doxorubicin's main competitors?

Direct comparators (same drug class / molecular target / therapeutic area): Skelid, Vibramycin, Chlorhexidin, Adriamycin, Doxycyclin, Zometa.

How often does this brief refresh?

Every 30 minutes from primary sources (FDA, EMA, MHRA, PMDA, ClinicalTrials.gov, USPTO). Subscribe to the RSS feed below for push alerts.

How do I get this as a recurring report?

Subscribe to /feed/ci/liposomal-doxorubicin.xml in any RSS reader (Feedly, Inoreader, NewsBlur). Every regulatory action, trial readout, or patent event lands in your feed automatically.

Last reviewed 2026-05-16 · How we verify

Liposomal Doxorubicin — Competitive Intelligence Brief

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Liposomal Doxorubicin (liposomal-doxorubicin) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: doxorubicin. Area: Oncology.

marketed doxorubicin 72 kDa type IV collagenase Oncology Live · refreshed every 30 min

Target snapshot

Liposomal Doxorubicin (liposomal-doxorubicin) — Pfizer.

Comparator set (6 drugs)

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
Liposomal Doxorubicin TARGET	liposomal-doxorubicin	Pfizer	marketed	doxorubicin	72 kDa type IV collagenase	1974-01-01
Skelid	TILUDRONIC ACID		marketed	Bisphosphonate	72 kDa type IV collagenase	1997-01-01
Vibramycin	doxycycline	Generic (originally Pfizer)	marketed	Tetracycline antibiotic	72 kDa type IV collagenase, Stromelysin-1, Collagenase 3	1967-01-01
Chlorhexidin	Chlorhexidin	Krishnadevaraya College of Dental Sciences & Hospital	marketed		Synaptojanin-2, 72 kDa type IV collagenase, Matrix metalloproteinase-9
Adriamycin	Adriamycin	Johann Wolfgang Goethe University Hospital	marketed		Canalicular multispecific organic anion transporter 1, Multidrug resistance-associated protein 6, 72 kDa type IV collagenase
Doxycyclin	Doxycyclin	Bulovka Hospital	marketed		72 kDa type IV collagenase, Stromelysin-1, Collagenase 3
Zometa	Zometa	University of Arkansas	marketed		Butyrophilin subfamily 3 member A1, 72 kDa type IV collagenase, Geranylgeranyl pyrophosphate synthase

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

2027-12-19 — Vibramycin · 7749532 · Formulation · US

Sponsor landscape (doxorubicin class)

Pfizer · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). Liposomal Doxorubicin — Competitive Intelligence Brief. https://druglandscape.com/ci/liposomal-doxorubicin. Accessed 2026-05-16.

Build your own brief

Pick any drug + add comparators:

https://druglandscape.com/ci/{slug} — auto-detected competitors
https://druglandscape.com/ci/{slug}?vs=drug1,drug2,drug3 — explicit comparators
Brand names auto-resolve: /ci/keytruda → 301 → /ci/pembrolizumab